HOME > TOP STORIES

TOP STORIES

REGULATORY Preparations Underway for MHLW to Set Up Private Third-Party Committee

September 16, 2011
REGULATORY Council Recommends 5 Drugs as Appropriate for Application Based on Info. in Public Domain

September 16, 2011
BUSINESS Small, Medium-Sized Generic Drug Makers’ Business Improves Amid Uncertainty Over Future

September 15, 2011
BUSINESS Supreme Court Rules Against GE Drug Makers, Allows Patent Extension for Eisai’s Aricept

September 15, 2011
ACADEMIA NCGM Hospital Removes Actos from List of Recommended Drugs in Diabetes Manual

September 14, 2011
ORGANIZATION FPMAJ Announces Its Basic Policy on Providing Info. on Drugs Used Off-label

September 13, 2011
BUSINESS Takeda Initiates PIII Trials of Antidiabetic TAK-875 in Japan

September 13, 2011
BUSINESS NBI Initiates PIII Study for BIBF1122 in Japan

September 12, 2011
REGULATORY MHLW Director-General Kikura Indicates “Firm Resolve” for Structural Improvement to Eliminate Drug Disasters

September 12, 2011
ACADEMIA Clinical Positioning Needs to Be Clarified for Nexavar, Sutent: Prof. Naito of Kyushu Univ.

September 12, 2011
REGULATORY MHLW’s Council to Draw Up 10-Year Strategy for Hepatitis

September 9, 2011
REGULATORY Council Recommends Subsidization of Peginterferon Therapy for Chronic Active Hepatitis B

September 9, 2011
BUSINESS Eisai to Accelerate Clinical Development with Milestone Payments, Signs Agreement on PIII Trials for Lenvatinib

September 8, 2011
REGULATORY CSIMC Introduces New Rule for Pricing of High-Priced Drugs; 10 Drugs to Be Reimbursed on Piecework under DPC

September 8, 2011
REGULATORY Some CSIMC Members Question NHI Pricing of Nexium Priced at Lower Level Than Omepral

September 8, 2011
REGULATORY CSIMC Recommends NHI Price Listing for 15 APIs/20 Products

September 7, 2011
ACADEMIA ”Seller’s Market” for Pharmacists Expected to Continue Over Next Few Years

September 7, 2011
ORGANIZATION JGA to Prepare Transparency GLs

September 6, 2011
ORGANIZATION Gaining Piece of the Pie in Growing Market “Best for Fast Results”: Keizai Doyukai’s Hasegawa

September 6, 2011
REGULATORY Pharmaceutical Industry Fully Sufficient as Export Industry: METI Minister Hachiro

September 5, 2011

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch

By Ken Yoshino

Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…